ADC Therapeutics (ADC Therapeutics) Total Assets : $354.78 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Total Assets?

ADC Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $354.78 Mil.

During the past 12 months, ADC Therapeutics's average Total Assets Growth Rate was -53.70% per year. During the past 3 years, the average Total Assets Growth Rate was 0.70% per year. During the past 5 years, the average Total Assets Growth Rate was 58.30% per year.

During the past 8 years, ADC Therapeutics's highest 3-Year average Total Assets Growth Rate was 134.40%. The lowest was 0.70%. And the median was 95.10%.

Total Assets is connected with ROA %. ADC Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -83.44%. Total Assets is also linked to Revenue through Asset Turnover. ADC Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.04.

ADC Therapeutics Total Assets Historical Data

The historical data trend for ADC Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Total Assets Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

137.68

513.69

617.97

490.86

354.78

ADC Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															490.86	467.67	507.30	466.90	354.78

ADC Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

ADC Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-148.249	+	503.031
	=	354.78

ADC Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-148.249	+	503.031
	=	354.78

ADC Therapeutics (NYSE:ADCT) Total Assets Explanation

Total Assets is connected with ROA %.

ADC Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-342.812	/	( (466.9	+	354.782)	/ 2 )
	=	-342.812	/	410.841
	=	-83.44 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

ADC Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	16.79	/	( (466.9	+	354.782)	/ 2 )
=	16.79	/	410.841
=	0.04

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

ADC Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.